AgingResearch.NewsJoin free

KIF2C agonist

KIF2C agonist has been studied in 2 papers since 2025: none in people yet, 2 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 1, 2026: “Compound extends lifespan in mice with premature aging”.

Intervention

2 papers study it6 findingsUpdated

1 new paper in 30 daysSee all 2

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: European Commission and 2 more
  • Animals2

What did studies of KIF2C agonist find?

5

Studies of KIF2C agonist measured 5 outcomes; the most studied are healthspan (2 studies), lifespan (1) and nuclear envelope invagination assembly (1).

Healthspan

upin mice2

2 studies

  1. KIF2C agonist improves healthspan in mice (progeria mice).

    “subcutaneous administration of the KIF2C agonist in progeria mice mitigates aging phenotypes and extends both health and lifespan.”

    Animalsprogeria mice

    Compound extends lifespan in mice with premature aging

    Nature communications

  2. KIF2C agonist improves healthspan in mice (progeria).

    “subcutaneous administration of the KIF2C agonist in progeria mice mitigated aging phenotypes, extending their healthspan.”

    Animalsprogeria

    Chemical enhancement of DNA repair in aging

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Lifespan

upin mice1

1 study

  1. KIF2C agonist extends lifespan in mice (progeria mice).

    “subcutaneous administration of the KIF2C agonist in progeria mice mitigates aging phenotypes and extends both health and lifespan.”

    Animalsprogeria mice

    Compound extends lifespan in mice with premature aging

    Nature communications

Nuclear envelope invagination assembly

upin human cells1

1 study

  1. KIF2C agonist increases nuclear envelope invagination assembly in human cells (aged and patient-derived cells).

    “by restoring the assembly of nuclear envelope invaginations driven by cytoplasmic microtubules.”

    Cellsaged and patient-derived cells

    Compound extends lifespan in mice with premature aging

    Nature communications

double-strand break DNA repair

upin human cells1

1 study

  1. KIF2C agonist increases double-strand break DNA repair in human cells.

    “the KIF2C agonist improves double-strand break (DSB) DNA repair in aged and patient-derived cells”

    Cellsaged and patient-derived cells, including Hutchinson-Gilford progeria syndrome and Down syndrome

    Compound extends lifespan in mice with premature aging

    Nature communications

DNA repair

upin cells1

1 study

  1. KIF2C agonist activates DNA repair in HGPS and DS.

    “a small-molecule agonist of KIF2C enhances DNA repair in two distinct genetic disorders exhibiting DNA damage and accelerated aging, the Hutchinson-Gilford progeria (HGPS) and Down (DS) syndromes.”

    Cellsin HGPS and DS

    Chemical enhancement of DNA repair in aging

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on DNA repair

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Nature Communications

Compound extends lifespan in mice with premature aging

In an animal experiment, a compound that activated a DNA repair protein eased aging-related features in mice with a premature-aging disorder.In an animal experiment, a compound that activated a DNA repair protein eased aging-related features in mice with a premature-aging disorder.

Mouse studyInterventions
Paper

Related